Article
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Oncotarget - 20 Sept 2016
Zemanova Jana, Hylse Ondrej, Collakova Jana, Vesely Pavel, Oltova Alexandra, Borsky Marek, Zaprazna Kristina, Kasparkova Marie, Janovska Pavlina, Verner Jan, Kohoutek Jiri, Dzimkova Marta, Bryja Vitezslav, Jaskova Zuzana, Brychtova Yvona, Paruch Kamil, Trbusek Martin
Abstract excerpt
Treatment options for TP53-mutated lymphoid tumors are very limited. In experimental models, TP53-mutated lymphomas were sensitive to direct inhibition of checkpoint kinase 1 (Chk1), a pivotal regulator of replication. We initially tested the potential of the highly specific Chk1 inhibitor SCH900776 to synergize with nucleoside analogs (NAs) fludarabine, cytarabine and gemcitabine in cell lines derived from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.